How to Come Off Tirzepatide: What the Evidence and Guidance Actually Say

What SURMOUNT-4 showed about discontinuing tirzepatide

The clearest evidence on what happens when you stop comes from the SURMOUNT-4 extension trial. Participants had lost an average of around 21% of their body weight during an open-label lead-in on tirzepatide; half then continued treatment and half switched to placebo. Over the following year, the group that stopped regained approximately 14 percentage points of weight, landing at roughly 3.5–5% below baseline, a meaningful but partial net loss. Those who continued lost a further 6% on average. The trial did not test tapering versus abrupt stopping; it compared continuation against complete discontinuation. What it confirms is that for most people, the medicine is actively working to suppress appetite and regulate energy balance, and that effect diminishes when it leaves your system.

This matters practically. If your plan is to stop because you have reached your target weight and feel confident about maintaining it through diet and activity, the evidence suggests that confidence should be high and the lifestyle groundwork solid before you make that call. The question of when to stop is at least as important as how.

Is there a recommended way to taper the dose?

There is no officially licensed tapering protocol for tirzepatide. The Mounjaro Summary of Product Characteristics does not describe a structured wind-down schedule in the way that, say, steroid prescriptions do. NHS patient guidance, including the NHS tirzepatide medicines page, advises patients to talk to their doctor or pharmacist before stopping any medicine and to follow the instructions in the Patient Information Leaflet.

In practice, some prescribers choose a gradual step-down (moving from a maintenance dose back through lower strengths over several weeks) on the basis that this may soften the rebound in appetite. Others discontinue directly. Neither approach has been tested head-to-head in a robust clinical trial, so the choice depends on your clinical picture: how long you have been on treatment, which dose you are on, your reasons for stopping, and whether there are other health factors in play. The general guidance on stopping Mounjaro explores this in more detail, but the short answer is: your prescriber should decide the method, not an online protocol.

If you order through a registered private pharmacy such as nume, every repeat order goes through a clinical re-review. That also applies if you are stopping: our prescribers can structure the conversation about whether a step-down approach makes sense for you specifically.

Common reasons people stop, and how the reason changes the plan

Not everyone stopping tirzepatide is doing so by choice. The reasons vary, and they shape what a sensible stopping plan looks like.

Side effects are one driver. Persistent nausea, vomiting, or severe gastrointestinal symptoms that do not settle after dose adjustment can make continuing impractical. In those cases, stopping (or stepping back to a lower dose) is a straightforward clinical response. A useful starting point is understanding what to expect in the first week, since many GI symptoms peak early and settle.

Pregnancy planning is another common reason. Tirzepatide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and the MHRA advises using effective contraception during treatment and for a wash-out period before attempting to conceive. Your prescriber should be involved in timing this transition.

Surgery is a third. NHS England guidance is clear that your surgical and anaesthetic team should know you are taking a GLP-1 medicine before any procedure, and some teams request a pause in treatment beforehand. The timing is a decision for your clinical team, not something to judge from a forum.

Then there is the straightforward scenario: you have achieved a stable, healthy weight, feel well, and want to see whether you can maintain it. That is a legitimate goal. The honest clinical conversation at that point covers what monitoring is sensible, what the regain data shows, and what the re-entry plan looks like if weight climbs again. On how quickly tirzepatide works and sustains results, the evidence is fairly consistent, but sustained results require sustained treatment for most people.

Cost, convenience and re-starting: practical considerations

Some people pause treatment for practical reasons rather than medical ones, a holiday, a quiet month financially, or wanting a break after a long period on treatment. That is understandable. It is worth knowing that restarting after a gap typically means returning to a lower dose, since your tolerance to the GI effects resets. A prescriber should guide that re-titration; it is not something to self-manage.

If cost is part of the calculation, the UK pricing context for Mounjaro is worth reading before you decide, particularly given Eli Lilly's list-price changes from September 2025. And if you are thinking about pausing around a holiday or a big week (payday, a work trip, Christmas) it is worth flagging to your prescriber in advance, since they can advise on the best timing for any dose change and what to watch for when you restart. A planned pause is safer than an abrupt one taken without clinical input.

Private weight-loss treatment pricing, including what is included in a single transparent cost, is set out on the treatment options page if that is useful context for your decision.